Mylan And Biocon Launch Semglee Insulin Glargine In US
Seeking Biosimilar Status And Interchangeability Designation For Lantus Rival
Mylan and Biocon have launched their Semglee version of insulin glargine in the US, revealing pricing details for the Lantus rival. At the same time, the firms have offered an update on their attempts to have Semglee classified as a biosimilar as they seek an interchangeability designation.
You may also be interested in...
Viatris has revealed its commercial strategy for its Semglee insulin glargine biosimilar in the US after winning a landmark first designation of interchangeability for the product from the FDA that will allow pharmacy-level substitution with a year of exclusivity.
In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.
Industry chiefs and experts, including Sandoz' global head of biopharmaceuticals, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.